Patent
Our Docket: GEN5-7.1CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: WADSWORTH et al.

Serial No. 10/656,474

Filed: 09/04/2003

For: IMPROVED AAV VECTORS FOR GENE
THERAPY

Patent
Our Docket: GEN5-7.1CON

Art Unit: 3736
Exainer: Not Assigned

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450

Jan'av 30

Signature of person mailing correspondence

Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequences under 37 C.F.R. § 1.821

In accordance with 37 C.F.R. § 1.821(e), Applicants hereby submit a computer readable form of the Sequence Listing for the instant application in the form of a compact disk. The Sequence Listing contained therein conforms to the requirements of 37 C.F.R 1.821- 1.824. Applicants also hereby submit the statement required under 37 C.F.R. § 1.821(f) and 37 C.F.R. § 1.821(g) that the sequence listing information recorded in computer readable form (compact disk) is identical to the written (paper copy) of the sequence listing in the instant application and contains no new matter. Applicants have enclosed a copy of the Notice to Comply with this response.

The Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for any additional fees required in connection with the filing of this Information Disclosure Statement.

Date:


15:

Jennifer D. Tousignant Agent for Applicants Registration No. 54,498

Respectfully submitted

Genzyme Corporation 15 Pleasant Street Connector P.O. Box 9322 Framingham, Massachusetts 01701-9322

Telephone: (508) 270-2553 Facsimile: (508) 872-5415



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/656,474

09/04/2003

Samuel C. Wadsworth

GEN5-7.1 CON

CONFIRMATION NO. 8696

FORMALITIES LETTER

OC000000011364867

24536 GENZYME CORPORATION LEGAL DEPARTMENT 15 PLEASANT ST CONNECTOR FRAMINGHAM, MA 01701-9322

Date Mailed: 11/26/2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE